As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and evidence based studies. One example of such study is the economic burden of disease.
Axtria recently collaborated on a study to analyze the "Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population".
The economic burden associated with irritable bowel syndrome with diarrhea (IBS-D) is not well understood. The objective of the study was to evaluate total annual all-cause, gastrointestinal-related, and symptom-related healthcare resource use and costs among IBS-D patients in a U.S. commercially insured population and also estimate incremental all-cause health care costs of IBS-D patients versus matched controls.
The study concluded that IBS-D was associated with a substantial burden of direct costs in this population. Compared with matched controls, IBS-D patients had greater medical service use and incurred significantly more annual all-cause health care costs, even after controlling for demographics and comorbidities. Incremental costs associated with IBS-D were primarily attributable to increased use of medical services rather than pharmacy costs.
If you are interested in talking directly to our experts involved in this study, please reach out to email@example.com and we would be happy to set-up a meeting.